Table 3 Adherence to recommended vaccine schedules for all adults included in the study and for those included in sensitivity analyses with prespecified lengths of baseline (pre-vaccine) data and follow-up data after the first vaccine of the series
Baseline | Continuous data available in follow-up period | |||||
|---|---|---|---|---|---|---|
Adherence | All adults | 18/24-moa | 6 months | 12 months | 18 months | 24 months |
Hepatitis A, n | 374,881 | 279,451 | 353,880 | 322,533 | 293,056 | 264,522 |
To 2nd dose, n (%) | 42,294 (11.3) | 30,020 (10.7) | 42,266 (11.9) | 41,056 (12.7) | 38,134 (13.0) | 34,851 (13.2) |
Hepatitis B, n | 71,634 | 52,734 | 67,076 | 60,685 | 54,872 | 49,142 |
To 2nd dose, n (%) | 32,951 (46.0) | 24,398 (46.3) | 31,217 (46.5) | 28,160 (46.4) | 25,450 (46.4) | 22,719 (46.2) |
To 3rd dose, n (%) | 15,564 (21.7) | 11,588 (22.0) | 15,321 (22.8) | 13,888 (22.9) | 12,574 (22.9) | 11,251 (22.9) |
Hepatitis A/B, n | 10,335 | 7746 | 9673 | 8764 | 7869 | 7056 |
To 2nd dose, n (%) | 5822 (56.3) | 4525 (58.4) | 5534 (57.2) | 5024 (57.3) | 4481 (56.9) | 4004 (56.8) |
To 3rd dose, n (%) | 1076 (10.4) | 840 (10.8) | 1073 (11.1) | 1002 (11.4) | 895 (11.4) | 808 (11.5) |